Biologic Therapies for Wound Care: Technologies and Global Markets
Report Scope:
This report studies the global market for wound care biologics. It describes different types of wound care biologics, including cellular and/or tissue-based products (CTPs), skin substitutes and topical agents, and their current and historical market revenues.
Skin substitutes are categorized into acellular and cellular composition, as well as biologic and bioengineered materials. Biologic skin substitutes are categorized into allografts and acellular animal derived tissue-based products or xenografts. Bioengineered skin substitutes are categorized into cellular and acellular or biosynthetic.
This report also studies applications for biologics in the care of chronic wounds and acute wounds. The market for chronic wounds includes venous leg ulcers, diabetic foot ulcers, pressure ulcers, and arterial and other ulcers. The market for acute wounds includes surgical and traumatic wounds and burns. An in-depth analysis of the market includes historical data and market projections based on sales by product type, application, end user and region. The report provides discusses the competitive landscape, key competitors and their respective market shares.
The scope of this report does not include biologics used for soft tissue reinforcement during plastic and reconstructive surgery. Such surgery is performed to treat structures of the human body that are affected aesthetically or functionally due to defects and abnormalities.
Report Includes:
This report studies the global market for wound care biologics. It describes different types of wound care biologics, including cellular and/or tissue-based products (CTPs), skin substitutes and topical agents, and their current and historical market revenues.
Skin substitutes are categorized into acellular and cellular composition, as well as biologic and bioengineered materials. Biologic skin substitutes are categorized into allografts and acellular animal derived tissue-based products or xenografts. Bioengineered skin substitutes are categorized into cellular and acellular or biosynthetic.
This report also studies applications for biologics in the care of chronic wounds and acute wounds. The market for chronic wounds includes venous leg ulcers, diabetic foot ulcers, pressure ulcers, and arterial and other ulcers. The market for acute wounds includes surgical and traumatic wounds and burns. An in-depth analysis of the market includes historical data and market projections based on sales by product type, application, end user and region. The report provides discusses the competitive landscape, key competitors and their respective market shares.
The scope of this report does not include biologics used for soft tissue reinforcement during plastic and reconstructive surgery. Such surgery is performed to treat structures of the human body that are affected aesthetically or functionally due to defects and abnormalities.
Report Includes:
- 23 data tables and 44 additional tables
- An up-to-date overview of the global markets for wound care biologics within the industry
- Analyses of the global market trends, with historic revenue (sales) data for 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
- Characterization and quantification of the market potential for wound care biologics, and market size estimation and forecast by product type, composition, application, end user vertical, and geographic region
- Description of the integumentary system, wound classifications and wound healing process, and discussion on ECM composition and its importance in skin wound healing
- Insight into the recent government regulations, reimbursement procedures, technological updates, 510 (K) approvals, and active clinical trials in wound care biologics that can shape the future marketplace
- In-depth information (facts and figures) concerning market drivers, challenges and issues, and other macroeconomic forces influencing the progress of this market
- Market share analysis of the key companies operating in the industry and Porter’s five forces analysis and their impact on the global market for wound care biologics
- Descriptive company profiles of major global players, including AlloSource, Bioventus LLC, BioTissue Inc., Integra LifeSciences Corp., MiMedx, Stryker Corp., and Smith & Nephew, Plc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Integumentary System
Wound Classifications
Wound Healing Process
Hemostasis
Inflammation
Proliferation
Maturation or Remodeling
ECM Composition and Its Importance in Skin Wound Healing
Biological Therapies for Wound Care
Autologous
Allogenic
Heterologous/Xenogeneic
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Favorable Global Demographics and Aging Population
Greater Incidence of Non-Communicable/Chronic Diseases
Increasing Acceptance of Regenerative Technologies and Protocols for Complex Wound Treatment
Increasing Technology Innovations and New Product Developments
Improving Reimbursement Environment
Market Restraints
High Cost
Reimbursement and Pricing Issues
Changing Regulatory Landscape
Market Opportunities
Market Consolidation
Underpenetrated Markets Outside the U.S.
Impact of COVID-19 on the Global Market for Wound Biologics
CHAPTER 5 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Overview
CTPs or Skin Substitutes
Topical Agents
Growth Factors
Global Market for Wound Biologics by Product Type
CTPs or Skin Substitute Types
Acellular
Cellular
Global Market for CTPs/Skin Substitutes, by Composition Type
Based on Type of Material
Biologic Skin Substitutes/Biologic Grafts
Bioengineered Skin Substitutes/Bioengineered Grafts
Global Market for CTPs/Skin Substitutes by Material
Global Market for Biologic CTPs/Skin Substitutes by Tissue Source
Global Market for Bioengineered Skin Substitutes by Composition Type
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Chronic Wounds
Common Types of Chronic Wounds
Acute Wounds
Common Types of Acute Wounds
Global Market for Wound Care Biologics by Wound Type
Global Market for Chronic Wound Care Biologics by Wound Type
Global Market for Acute Wound Care Biologics by Wound Type
CHAPTER 7 MARKET BREAKDOWN BY REGION
Global Market for Wound Care Biologics by Region
North America
Market Analysis
Market Revenue
Europe
Market Analysis
Market Revenue
Asia-Pacific
Market Analysis
Market Revenue
Rest of World
Market Analysis
Market Revenue
CHAPTER 8 MARKET BREAKDOWN BY END USER
Hospital Outpatient Wound Centers
Inpatient Settings/Hospitals
Office or Clinic Settings
Global Market for Wound Care Biologics by End User
CHAPTER 9 REGULATORY STRUCTURE AND NEW PRODUCT DEVELOPMENTS
FDA Regulatory Review and Approval Process Governing CTPs or Skin Substitutes
Premarket Approval
510(k) Clearance
Biologics License Application
361 Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps)
Humanitarian Device Exemption
Coverage and Reimbursement
Medicare Coverage
Medicaid
Private Payers
FDA Approvals for Wound Care Biologics by Approval Type
510 (K) Approvals
BLA Approvals
Wound Care Biologics in Clinical Development
Products
Applications
CHAPTER 10 COMPETITIVE LANDSCAPE
Overview
Market Shares of Leading Companies
Key Market Players by Product Type
Allografts
Acellular Animal Derived Tissue-Based Products/Xenografts
Cellular Bioengineered
Acellular Bioengineered/Biosynthetic
Topical Agents
Porter's Five Forces Analysis
CHAPTER 11 COMPANY PROFILES
3M
ALLERGAN AESTHETICS
ALLOSOURCE
AROA BIOSURGERY LTD.
AZIYO BIOLOGICS
BIOTISSUE INC.
BIOVENTUS LLC
CONVATEC GROUP PLC
COOK BIOTECH INC.
INTEGRA LIFESCIENCES HOLDINGS CORP.
MALLINCKRODT PLC
MIMEDX
MTF BIOLOGICS
ORGANOGENESIS HOLDINGS INC.
SKYE BIOLOGICS HOLDINGS, LLC
SMITH & NEPHEW, PLC
STIMLABS LLC
STRYKER CORP.
ZIMMER BIOMET HOLDINGS INC.
CHAPTER 12 APPENDIX: ACRONYMS
Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Integumentary System
Wound Classifications
Wound Healing Process
Hemostasis
Inflammation
Proliferation
Maturation or Remodeling
ECM Composition and Its Importance in Skin Wound Healing
Biological Therapies for Wound Care
Autologous
Allogenic
Heterologous/Xenogeneic
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Favorable Global Demographics and Aging Population
Greater Incidence of Non-Communicable/Chronic Diseases
Increasing Acceptance of Regenerative Technologies and Protocols for Complex Wound Treatment
Increasing Technology Innovations and New Product Developments
Improving Reimbursement Environment
Market Restraints
High Cost
Reimbursement and Pricing Issues
Changing Regulatory Landscape
Market Opportunities
Market Consolidation
Underpenetrated Markets Outside the U.S.
Impact of COVID-19 on the Global Market for Wound Biologics
CHAPTER 5 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Overview
CTPs or Skin Substitutes
Topical Agents
Growth Factors
Global Market for Wound Biologics by Product Type
CTPs or Skin Substitute Types
Acellular
Cellular
Global Market for CTPs/Skin Substitutes, by Composition Type
Based on Type of Material
Biologic Skin Substitutes/Biologic Grafts
Bioengineered Skin Substitutes/Bioengineered Grafts
Global Market for CTPs/Skin Substitutes by Material
Global Market for Biologic CTPs/Skin Substitutes by Tissue Source
Global Market for Bioengineered Skin Substitutes by Composition Type
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Chronic Wounds
Common Types of Chronic Wounds
Acute Wounds
Common Types of Acute Wounds
Global Market for Wound Care Biologics by Wound Type
Global Market for Chronic Wound Care Biologics by Wound Type
Global Market for Acute Wound Care Biologics by Wound Type
CHAPTER 7 MARKET BREAKDOWN BY REGION
Global Market for Wound Care Biologics by Region
North America
Market Analysis
Market Revenue
Europe
Market Analysis
Market Revenue
Asia-Pacific
Market Analysis
Market Revenue
Rest of World
Market Analysis
Market Revenue
CHAPTER 8 MARKET BREAKDOWN BY END USER
Hospital Outpatient Wound Centers
Inpatient Settings/Hospitals
Office or Clinic Settings
Global Market for Wound Care Biologics by End User
CHAPTER 9 REGULATORY STRUCTURE AND NEW PRODUCT DEVELOPMENTS
FDA Regulatory Review and Approval Process Governing CTPs or Skin Substitutes
Premarket Approval
510(k) Clearance
Biologics License Application
361 Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps)
Humanitarian Device Exemption
Coverage and Reimbursement
Medicare Coverage
Medicaid
Private Payers
FDA Approvals for Wound Care Biologics by Approval Type
510 (K) Approvals
BLA Approvals
Wound Care Biologics in Clinical Development
Products
Applications
CHAPTER 10 COMPETITIVE LANDSCAPE
Overview
Market Shares of Leading Companies
Key Market Players by Product Type
Allografts
Acellular Animal Derived Tissue-Based Products/Xenografts
Cellular Bioengineered
Acellular Bioengineered/Biosynthetic
Topical Agents
Porter's Five Forces Analysis
CHAPTER 11 COMPANY PROFILES
3M
ALLERGAN AESTHETICS
ALLOSOURCE
AROA BIOSURGERY LTD.
AZIYO BIOLOGICS
BIOTISSUE INC.
BIOVENTUS LLC
CONVATEC GROUP PLC
COOK BIOTECH INC.
INTEGRA LIFESCIENCES HOLDINGS CORP.
MALLINCKRODT PLC
MIMEDX
MTF BIOLOGICS
ORGANOGENESIS HOLDINGS INC.
SKYE BIOLOGICS HOLDINGS, LLC
SMITH & NEPHEW, PLC
STIMLABS LLC
STRYKER CORP.
ZIMMER BIOMET HOLDINGS INC.
CHAPTER 12 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table B: Global Market for CTPs/Skin Substitutes, by Composition Type, Through 2026
Summary Table A: Global Market for Wound Care Biologics, by Product Type, Through 2026
Table 1: ECM Components and Their Roles in Wound Healing
Table 2: Number and Distribution of Persons Age 60+, by Region, 2019 and 2050
Table 3: Global Prevalence of Diabetes, by Population Segment, Through 2045
Table 4: Age-Adjusted Comparative Prevalence of Diabetes, by Country, 2010–2045
Table 5: Recent Deals and Acquisitions in Wound Biologics Market, 2017–Jan. 2022
Table 6: Proteolytic Enzymes for Wound Treatment
Table 7: Commercially Available Topical Agents
Table 8: Global Market for Wound Care Biologics, by Product Type, Through 2026
Table 9: Proprietary CTPs/Skin Substitutes Processing Technologies
Table 10: Global Market for CTPs/Skin Substitutes, by Composition Type, Through 2026
Table 11: Placental Allograft
Table 12: Dermal Allografts/Allograft Dermal Matrices
Table 13: Acellular Animal-Derived Tissue-Based Products/Xenografts
Table 14: Human Cellular Bioengineered Skin Substitutes
Table 15: Biosynthetic Skin Substitutes
Table 16: Global Market for CTPs/Skin Substitutes, by Material, Through 2026
Table 17: Global Market for Biologic CTPs/Skin Substitutes, by Tissue Source, Through 2026
Table 18: Global Market for Bioengineered Skin Substitutes, by Composition Type, Through 2026
Table 19: Pressure Ulcer Staging
Table 20: Burn Classifications
Table 21: Global Market for Wound Care Biologics, by Wound Type, Through 2026
Table 22: Biologics in Clinical Trials for DFU Treatment
Table 23: Global Market for Chronic Wound Care Biologics, by Wound Type, Through 2026
Table 24: Biologics in Clinical Trials for Burn Treatment
Table 25: Global Market for Acute Wound Care Biologics, by Wound Type, Through 2026
Table 26: Global Market for Wound Care Biologics, by Region, Through 2026
Table 27: North American Market for Wound Care Biologics, by Product Type, Through 2026
Table 28: North American Market for Wound Care Biologics, by Country, Through 2026
Table 29: European Market for Wound Care Biologics, by Product Type, Through 2026
Table 30: European Market for Wound Care Biologics, by Country, Through 2026
Table 31: Demographic and Healthcare Statistics for European Countries, 2020
Table 32: Asia-Pacific Market for Wound Care Biologics, by Product Type, Through 2026
Table 33: Asia-Pacific Market for Wound Care Biologics, by Country, Through 2026
Table 34: Demographic and Healthcare Statistics for Asia-Pacific Countries, 2020
Table 35: RoW Market for Wound Care Biologics, by Product Type, Through 2026
Table 36: Global Market for Wound Care Biologics, by End User, Through 2026
Table 37: 510 (K) Approvals for Wound Care Biologics, Jan. 2018–Feb. 2022
Table 38: BLA Approvals for Wound Care Biologics, Jan. 2018–Feb. 2022
Table 39: Wound Care Biologics in Clinical Development
Table 40: Shares of Leading Companies in the Global Market for Wound Care Biologics, 2021
Table 41: Key Wound Care Biologics Manufacturers' Offerings
Table 42: Leading Companies in Allografts
Table 43: Key Players' Allograft Offerings, by Product Type
Table 44: Leading Acellular Animal Derived Tissue-Based Products/Xenografts
Table 45: Porter's Five Forces Analysis of the Global Market for Wound Care Biologics
Table 46: 3M: Wound Care Biologics Portfolio
Table 47: Allergan: Wound Care Biologics Portfolio
Table 48: Allosource: Wound Care Biologics Portfolio
Table 49: Aroa Biosurgery: Wound Care Biologics Portfolio
Table 50: Aziyo Biologics: Wound Care Biologics Portfolio
Table 51: BioTissue: Wound Care Biologics Portfolio
Table 52: Bioventus: Wound Care Biologics Portfolio
Table 53: ConvaTec: Biologic Wound Care Product Portfolio
Table 54: Cook Biotech: Wound Care Biologics Portfolio
Table 55: Integra LifeSciences: Wound Care Biologics Portfolio
Table 56: Mallinckrodt: Wound Care Biologics Portfolio
Table 57: MiMedx: Wound Care Biologics Portfolio
Table 58: MTF Biologics: Wound Care Biologics Portfolio
Table 59: Organogenesis: Wound Care Biologics Portfolio
Table 60: Skye Biologics: Wound Care Biologics Portfolio
Table 61: Smith & Nephew: Biologic Wound Care Product Portfolio
Table 62: StimLabs: Wound Care Biologics Portfolio
Table 63: Stryker: Wound Care Biologics Portfolio
Table 64: Zimmer Biomet: Wound Care Biologics Portfolio
Table 65: Acronyms Used in this Report
Summary Table B: Global Market for CTPs/Skin Substitutes, by Composition Type, Through 2026
Summary Table A: Global Market for Wound Care Biologics, by Product Type, Through 2026
Table 1: ECM Components and Their Roles in Wound Healing
Table 2: Number and Distribution of Persons Age 60+, by Region, 2019 and 2050
Table 3: Global Prevalence of Diabetes, by Population Segment, Through 2045
Table 4: Age-Adjusted Comparative Prevalence of Diabetes, by Country, 2010–2045
Table 5: Recent Deals and Acquisitions in Wound Biologics Market, 2017–Jan. 2022
Table 6: Proteolytic Enzymes for Wound Treatment
Table 7: Commercially Available Topical Agents
Table 8: Global Market for Wound Care Biologics, by Product Type, Through 2026
Table 9: Proprietary CTPs/Skin Substitutes Processing Technologies
Table 10: Global Market for CTPs/Skin Substitutes, by Composition Type, Through 2026
Table 11: Placental Allograft
Table 12: Dermal Allografts/Allograft Dermal Matrices
Table 13: Acellular Animal-Derived Tissue-Based Products/Xenografts
Table 14: Human Cellular Bioengineered Skin Substitutes
Table 15: Biosynthetic Skin Substitutes
Table 16: Global Market for CTPs/Skin Substitutes, by Material, Through 2026
Table 17: Global Market for Biologic CTPs/Skin Substitutes, by Tissue Source, Through 2026
Table 18: Global Market for Bioengineered Skin Substitutes, by Composition Type, Through 2026
Table 19: Pressure Ulcer Staging
Table 20: Burn Classifications
Table 21: Global Market for Wound Care Biologics, by Wound Type, Through 2026
Table 22: Biologics in Clinical Trials for DFU Treatment
Table 23: Global Market for Chronic Wound Care Biologics, by Wound Type, Through 2026
Table 24: Biologics in Clinical Trials for Burn Treatment
Table 25: Global Market for Acute Wound Care Biologics, by Wound Type, Through 2026
Table 26: Global Market for Wound Care Biologics, by Region, Through 2026
Table 27: North American Market for Wound Care Biologics, by Product Type, Through 2026
Table 28: North American Market for Wound Care Biologics, by Country, Through 2026
Table 29: European Market for Wound Care Biologics, by Product Type, Through 2026
Table 30: European Market for Wound Care Biologics, by Country, Through 2026
Table 31: Demographic and Healthcare Statistics for European Countries, 2020
Table 32: Asia-Pacific Market for Wound Care Biologics, by Product Type, Through 2026
Table 33: Asia-Pacific Market for Wound Care Biologics, by Country, Through 2026
Table 34: Demographic and Healthcare Statistics for Asia-Pacific Countries, 2020
Table 35: RoW Market for Wound Care Biologics, by Product Type, Through 2026
Table 36: Global Market for Wound Care Biologics, by End User, Through 2026
Table 37: 510 (K) Approvals for Wound Care Biologics, Jan. 2018–Feb. 2022
Table 38: BLA Approvals for Wound Care Biologics, Jan. 2018–Feb. 2022
Table 39: Wound Care Biologics in Clinical Development
Table 40: Shares of Leading Companies in the Global Market for Wound Care Biologics, 2021
Table 41: Key Wound Care Biologics Manufacturers' Offerings
Table 42: Leading Companies in Allografts
Table 43: Key Players' Allograft Offerings, by Product Type
Table 44: Leading Acellular Animal Derived Tissue-Based Products/Xenografts
Table 45: Porter's Five Forces Analysis of the Global Market for Wound Care Biologics
Table 46: 3M: Wound Care Biologics Portfolio
Table 47: Allergan: Wound Care Biologics Portfolio
Table 48: Allosource: Wound Care Biologics Portfolio
Table 49: Aroa Biosurgery: Wound Care Biologics Portfolio
Table 50: Aziyo Biologics: Wound Care Biologics Portfolio
Table 51: BioTissue: Wound Care Biologics Portfolio
Table 52: Bioventus: Wound Care Biologics Portfolio
Table 53: ConvaTec: Biologic Wound Care Product Portfolio
Table 54: Cook Biotech: Wound Care Biologics Portfolio
Table 55: Integra LifeSciences: Wound Care Biologics Portfolio
Table 56: Mallinckrodt: Wound Care Biologics Portfolio
Table 57: MiMedx: Wound Care Biologics Portfolio
Table 58: MTF Biologics: Wound Care Biologics Portfolio
Table 59: Organogenesis: Wound Care Biologics Portfolio
Table 60: Skye Biologics: Wound Care Biologics Portfolio
Table 61: Smith & Nephew: Biologic Wound Care Product Portfolio
Table 62: StimLabs: Wound Care Biologics Portfolio
Table 63: Stryker: Wound Care Biologics Portfolio
Table 64: Zimmer Biomet: Wound Care Biologics Portfolio
Table 65: Acronyms Used in this Report
LIST OF FIGURES
Summary Figure: Global Market for CTPs/Skin Substitutes, by Composition Type, 2019-2026
Figure 1: Human Skin
Figure 2: Stages of Wound Healing
Figure 3: Wound Healing Stages and Main Involved Components of the ECM
Figure 4: Transplantation of Autologous Cultured Epidermis
Figure 5: Global Geriatric Population (Age 65 and Above), 2014-2022
Figure 6: Clinical Trials Initiated for Wound Care Biologics, 2016-2021
Figure 7: Global Market Shares of Wound Care Biologics, by Product Type, 2020
Figure 8: Types of CTPs/Skin Substitutes Based on Composition
Figure 9: Global Market for CTPs/Skin Substitutes, by Composition Type, 2019-2026
Figure 10: Global Market Shares of CTPs/Skin Substitutes, by Composition Type, 2020
Figure 11: Human Placental Membrane Components
Figure 12: Types of CTPs/Skin Substitutes
Figure 13: Global Market for CTPs/Skin Substitutes, by Material, 2019-2026
Figure 14: Shares of Global Market for CTPs/Skin Substitutes, by Material, 2020
Figure 15: Global Market for Biologic CTPs/Skin Substitutes, by Tissue Source, 2019-2026
Figure 16: Global Market for Bioengineered Skin Substitutes, by Composition Type, 2019-2026
Figure 17: Shares of Global Market for Wound Care Biologics, by Wound Type, 2020
Figure 18: Shares of Global Market for Chronic Wound Care Biologics, by Wound Type, 2020
Figure 19: Shares of Global Market for Acute Wound Care Biologics, by Wound Type, 2020
Figure 20: Global Market for Wound Care Biologics, by Region, 2019-2026
Figure 21: Shares of Global Market for Wound Care Biologics, by Region, 2020
Figure 22: North American Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 23: European Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 24: Health Expenditures Per Capita for European Countries, 2015-2019
Figure 25: Asia-Pacific Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 26: RoW Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 27: Shares of Global Market for Wound Care Biologics, by End User, 2020
Figure 28: Active Clinical Trials for Wound Care Biologics, by Wound Type, March 2022
Figure 29: Aroa Biosurgery: Annual Revenue, 2018-2021
Figure 30: Aziyo Biologics: Annual Revenue, 2018-2021
Figure 31: Bioventus LLC: Annual Revenue, 2018-2021
Figure 32: Bioventus: Revenue Share, by Geographic Area, 2021
Figure 33: Integra LifeSciences: Wound Reconstruction and Care Segment, Annual Revenue, 2018-2021
Figure 34: Integra LifeSciences: Private Label Segment, Annual Revenue, 2018-2021
Figure 35: Integra LifeSciences: Revenue Share, by Geographic Area, 2020
Figure 36: MiMedx: Annual Revenue, 2018-2021
Figure 37: MiMedx: Revenue Share, by Product Class, 2021
Figure 38: Organogenesis: Advanced Wound Care Segment, Annual Revenue, 2018-2021
Figure 39: Smith & Nephew: Advanced Wound Management Segment, Annual Revenue, 2018-2021
Figure 40: Smith & Nephew: Advanced Wound Bioactive Segment, Annual Revenue, 2018-2021
Figure 41: Smith & Nephew: Revenue Share, by Geography, 2021
Figure 42: Stryker: Trauma and Extremities Segment, Annual Revenue, 2018-2021
Figure 43: Stryker: Trauma and Extremities Segment, Revenue Share, by Geography, 2021
Figure 44: Zimmer Biomet: S.E.T. Segment, Annual Revenue, 2018-2021
Figure 45: Zimmer Biomet: Revenue Share, by Geography, 2021
Summary Figure: Global Market for CTPs/Skin Substitutes, by Composition Type, 2019-2026
Figure 1: Human Skin
Figure 2: Stages of Wound Healing
Figure 3: Wound Healing Stages and Main Involved Components of the ECM
Figure 4: Transplantation of Autologous Cultured Epidermis
Figure 5: Global Geriatric Population (Age 65 and Above), 2014-2022
Figure 6: Clinical Trials Initiated for Wound Care Biologics, 2016-2021
Figure 7: Global Market Shares of Wound Care Biologics, by Product Type, 2020
Figure 8: Types of CTPs/Skin Substitutes Based on Composition
Figure 9: Global Market for CTPs/Skin Substitutes, by Composition Type, 2019-2026
Figure 10: Global Market Shares of CTPs/Skin Substitutes, by Composition Type, 2020
Figure 11: Human Placental Membrane Components
Figure 12: Types of CTPs/Skin Substitutes
Figure 13: Global Market for CTPs/Skin Substitutes, by Material, 2019-2026
Figure 14: Shares of Global Market for CTPs/Skin Substitutes, by Material, 2020
Figure 15: Global Market for Biologic CTPs/Skin Substitutes, by Tissue Source, 2019-2026
Figure 16: Global Market for Bioengineered Skin Substitutes, by Composition Type, 2019-2026
Figure 17: Shares of Global Market for Wound Care Biologics, by Wound Type, 2020
Figure 18: Shares of Global Market for Chronic Wound Care Biologics, by Wound Type, 2020
Figure 19: Shares of Global Market for Acute Wound Care Biologics, by Wound Type, 2020
Figure 20: Global Market for Wound Care Biologics, by Region, 2019-2026
Figure 21: Shares of Global Market for Wound Care Biologics, by Region, 2020
Figure 22: North American Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 23: European Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 24: Health Expenditures Per Capita for European Countries, 2015-2019
Figure 25: Asia-Pacific Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 26: RoW Market for Wound Care Biologics, by Product Type, 2019-2026
Figure 27: Shares of Global Market for Wound Care Biologics, by End User, 2020
Figure 28: Active Clinical Trials for Wound Care Biologics, by Wound Type, March 2022
Figure 29: Aroa Biosurgery: Annual Revenue, 2018-2021
Figure 30: Aziyo Biologics: Annual Revenue, 2018-2021
Figure 31: Bioventus LLC: Annual Revenue, 2018-2021
Figure 32: Bioventus: Revenue Share, by Geographic Area, 2021
Figure 33: Integra LifeSciences: Wound Reconstruction and Care Segment, Annual Revenue, 2018-2021
Figure 34: Integra LifeSciences: Private Label Segment, Annual Revenue, 2018-2021
Figure 35: Integra LifeSciences: Revenue Share, by Geographic Area, 2020
Figure 36: MiMedx: Annual Revenue, 2018-2021
Figure 37: MiMedx: Revenue Share, by Product Class, 2021
Figure 38: Organogenesis: Advanced Wound Care Segment, Annual Revenue, 2018-2021
Figure 39: Smith & Nephew: Advanced Wound Management Segment, Annual Revenue, 2018-2021
Figure 40: Smith & Nephew: Advanced Wound Bioactive Segment, Annual Revenue, 2018-2021
Figure 41: Smith & Nephew: Revenue Share, by Geography, 2021
Figure 42: Stryker: Trauma and Extremities Segment, Annual Revenue, 2018-2021
Figure 43: Stryker: Trauma and Extremities Segment, Revenue Share, by Geography, 2021
Figure 44: Zimmer Biomet: S.E.T. Segment, Annual Revenue, 2018-2021
Figure 45: Zimmer Biomet: Revenue Share, by Geography, 2021
